Showing results (31-40 of 95) with videos related to
Sort By:
Pageof 10
American Heart Journal|April 30, 2017
An examination of the relationship between serum uric acid level, a clinical history of gout, and cardiovascular outcomes among patients with acute coronary syndromeNeha J Pagidipati, Connie N Hess, Robert M Clare, et al.American Heart Journal|November 19, 2011
Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal functionChiara Melloni, Stefan K James, Jennifer A White, et al.Journal of the American College of Cardiology|November 6, 2012
Comparison of the prognosis of spontaneous and percutaneous coronary intervention-related myocardial infarctionSergio Leonardi, Laine Thomas, Megan L Neely, et al.American Heart Journal|September 11, 2013
Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trialAkshay Bagai, Jennifer A White, Yuliya Lokhnygina, et al.American Heart Journal|October 8, 2013
Association between bleeding and mortality among women and men with high-risk acute coronary syndromes: insights from the Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes (EARLY ACS) trialPadma Kaul, Jean-François Tanguay, L Kristin Newby, et al.Current Atherosclerosis Reports|May 7, 2022
ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and FutureArzu Kalayci, C Michael Gibson, Paul M Ridker, et al.The American Journal of Cardiology|December 4, 2014
Long-term outcomes and causes of death after acute coronary syndrome in patients in the Bologna, Italy, areaFabio Vagnarelli, Nevio Taglieri, Paolo Ortolani, et al.Circulation|February 9, 2011
Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trialTracy Y Wang, Jennifer A White, Pierluigi Tricoci, et al.American Heart Journal|September 24, 2016
Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarctionC Michael Gibson, Serge Korjian, Pierluigi Tricoci, et al.Archives of Internal Medicine|April 12, 2006
Clopidogrel to treat patients with non-ST-segment elevation acute coronary syndromes after hospital dischargePierluigi Tricoci, Matthew T Roe, Jyotsna Mulgund, et al.Pageof 10